Vehicles for oligonucleotide delivery to tumours

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Pharmacology

Background:

• Tumor vasculature offers a pathway for drug delivery to neoplastic cells.
• Enhanced permeability of tumor vasculature allows for selective drug targeting.
• Carrier-mediated delivery is crucial for genetic medicine to tumors.

Purpose of the Study:

• To review the potential of cationic liposomes and cyclodextrins (CyDs) for delivering therapeutic oligonucleotides (ONs) to tumors.
• To identify major hindrances to ON delivery posed by the tumor microenvironment.
• To compare different ON delivery agents for solid tumor treatment.

Main Methods:

• Discussion of cationic liposomes (100-200 nm) and cyclodextrins (CyDs, 1.5 nm) as ON delivery vehicles.
• Comparison of liposomes and CyDs with other agents: porphyrin derivatives, dendrimers, polyethylenimine, nanoparticles, and microspheres.
• Analysis of carrier chemical and physical properties influencing in vitro and in vivo cellular uptake of ONs.

Main Results:

• Cationic liposomes have a history in nucleic acid delivery to mammalian cells.
• CyDs are established for cholesterol efflux and emerging as nucleic acid delivery agents.
• Carrier properties significantly impact ON uptake into tumor cells, especially in vivo.

Conclusions:

• Cationic liposomes and CyDs show promise for therapeutic oligonucleotide delivery to tumors.
• Understanding carrier properties is key to overcoming tumor-specific delivery challenges.
• Further research is needed to optimize ON delivery systems for enhanced cancer therapy.